Patent ID: 11912776
Assignee: PFIZER INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 18:
19. The method of claim 13,
wherein the BCMA specific CAR comprises a CD8a signal peptide having the sequence of SEQ ID NO: 318; a VH region having the sequence of SEQ ID NO: 33; a GS linker having the sequence of SEQ ID NO: 333; a VL region having the sequence of SEQ ID NO: 34; a CD20 epitope having the sequence of SEQ ID NO: 398; a CD8a hinge having the sequence of SEQ ID NO: 320; a CD8α transmembrane domain having the sequence of SEQ ID NO: 322; a 4-1BB intracellular signaling domain having the sequence of SEQ ID NO: 323; and a CD3ζ intracellular signaling domain having the sequence of SEQ ID NO: 324;
wherein the BCMA specific CAR further comprises a stalk domain between the extracellular ligand-binding domain and the first transmembrane domain;
wherein the BCMA specific CAR further comprises a CD20 epitope;
wherein the BCMA specific CAR further comprises another extracellular ligand-binding domain that is not specific for BCMA binding;
wherein the engineered immune cell further comprises another CAR that is not specific for BCMA;
wherein the engineered immune cell further comprises a polynucleotide encoding a suicide polypeptide; or
wherein the engineered immune cell further comprises a disruption in one or more endogenous genes, wherein the endogenous gene encodes TCRα, TCRβ, CD52, glucocorticoid receptor (GR), deoxycytidine kinase (dCK), or an immune checkpoint protein.